US 20090042217A1

(19) **United States**
(12) **Patent Application Publication**
Brenner et al.

(10) **Pub. No.: US 2009/0042217 A1**
(43) **Pub. Date: Feb. 12, 2009**

(54) **METHODS AND KITS FOR DETERMINING BLOOD COAGULATION**

(75) Inventors: **Benjamin Brenner**, Haifa (IL); **Anat Aharon**, Kirya-Tivon (IL)

Correspondence Address:
Martin D. Moynihan
PRTSI
P.O. Box 16446
Arlington, VA 22215 (US)

(73) Assignee: **Rappaport Family Institute for Research in the Medical Sciences**, Haifa (IL)

(21) Appl. No.: **12/223,290**

(22) PCT Filed: **Jun. 23, 2008**

(86) PCT No.: **PCT/IL2007/000110**

§ 371 (c)(1),
(2), (4) Date: **Jul. 28, 2008**

Related U.S. Application Data

(60) Provisional application No. 60/762,519, filed on Jan. 27, 2006.

Publication Classification

(51) **Int. Cl.**
G01N 33/543 (2006.01)
C12Q 1/56 (2006.01)
G01N 33/53 (2006.01)

(52) **U.S. Cl.** **435/7.8**; 435/13; 435/7.92

(57) **ABSTRACT**

A method of determining a coagulation status of a blood sample is provided. The method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the ratio is indicative of the coagulation status of the blood sample.





Fig. 1a



Fig. 1b



Fig. 1c



Fig. 1d

Figure 2



Figure 3



Figure 4



Figure 5



Figure 6



METHODS AND KITS FOR DETERMINING BLOOD COAGULATION

FIELD AND BACKGROUND OF THE INVENTION

[0001] The present invention relates to a method and kit of determining blood coagulation.

[0002] Changes in the coagulation balance, due to procoagulant microparticles, is associated with hereditary or acquired thrombophilia, inflammatory complications, acute coronary syndromes and diseases such as diabetes mellitus and cancer. Hyper-coagulation predicts elevated risk for a thrombotic event, while hypocoagulation is associated with a bleeding tendency.

[0003] The procoagulant microparticles are small membrane vesicles that shed from various cellular surfaces. Cellular microparticles expose membrane antigens that are specific for the cells from which they are derived and they vary in size, phospholipid and protein composition [Diamant et al., Eur J Clin Invest (2004) 34:392-401]. There are two mechanisms that can result in microparticle formation—cell activation and apoptosis. Endothelial cells produce microparticles when exposed to cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor (TNF). Endothelial microparticles are detectable in normal human blood and are increased in patients with coagulation abnormalities. Concentration of circulating platelet microparticles (PMP) may serve as a marker of platelet activation. Procoagulant PMP are known to be elevated in severe thrombotic states [Preston et al., Hypertension (2003) 41:211-7]. Leukocyte-derived microparticles, bearing both tissue factor and P-Selectin glycoprotein ligand 1 (PSGL-1), circulate in blood and are accumulated in the developing platelet-rich thrombus following a vessel wall injury [Furie et al., Trends Mol Med (2004) 10:171-8].

[0004] A wide range of diseases demonstrate an increase in microparticles and are associated with procoagulability state. Endothelial microparticles are increased in patients with a coagulation abnormality associated with the lupus anticoagulant [Combes et al., J Clin Invest (1999) 104:93-102], and in acute coronary syndromes [Bernal-Mizrachi et al., Int J Cardiol (2004) 97:439-46]. Microparticles that shed from cancer cells constitute the main source TF activity and contribute to the prothrombotic effects associated cancer [Yu J L and Rak J W, J Thromb Haemost (2004) 2:2065-7]. In myeloproliferative syndromes, PMPs are elevated and provide a catalytic surface for thrombin generation that is associated with the increased risk for arterial or venous thrombotic event [Villmow et al., Thromb Res (2002) 108:139-45]. In patients with gastric cancer, PMP levels were significantly higher compared to healthy controls [Kanazawa et al., Lung Cancer (2003) 39:145-9]. Type 1 and Type 2 diabetes are also associated with increased levels of circulating microparticles. However, the procoagulant activity and the cellular origin of the microparticles differ in diabetic patients [Omoto et al., Nephron (1999) 81:271-7]. Normal pregnancies are characterized by high levels of platelet and endothelial microparticles compared to the levels of microparticles found in non-pregnant healthy women [Bretelle et al., Thromb Haemost (2003) 89:486-921.

[0005] Tissue Factor (TF), the initiator of coagulation, may appear in human plasma in a microparticle-associated or in a fluid-phase form. The microparticle associated form is capable of initiating thrombin production (FVII-mediated), while the fluid phase form does not cause thrombin generation [Sturk-Maquelin et al., J Thromb Haemost (2003) 1(9): 1920-6]. In order to maintain hemostatic balance and prevent hyper-coagulation, Tissue Factor Pathway Inhibitor (TFPI) inhibits the coagulation cascade by binding to factor VIIa/TF complex and to the active site of factor Xa consequently creating a quartet complex (TFPI/VIIa/TF/Xa). TFPI, which is found in circulating microparticles, was found to inhibit the enhanced TF activity in circulating MPs [Steppich et al., Thromb Haemost (2005) 93:35-9].

[0006] TF and TFPI antigens may also appear on intact cells, including endothelial cells and trophoblasts of the placenta, where they interact to maintain hemostatic balance. Endothelial cells possess an "anticoagulant character" and have been shown to express high TFPI protein levels and activity, while placental trophoblast cells possess a "procoagulant character" and have been shown to express high TF protein levels and activity [Aharon et al., Thromb Haemost (2004) 92:776-86].

[0007] At present, only a few commercially available coagulation assays and diagnostic kits exist. Screening tests, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), are most commonly used in clinical settings and measure the time it takes for a blood clot to form. The PT is the more convenient assay, and is performed by adding a large quantity of thromboplastin (TF) to the citrated plasma, with subsequent initiation of the reaction by calcium addition. The aPTT test involves a 3-5 minute preincubation of the citrated plasma with a mixture of phospholipids and negatively charged solid surfaces. The reaction is initiated by adding calcium. For both assays, the time to clot formation is evaluated. Although both assays are well established, neither assay entirely mimics the physiological coagulation reaction. For example, in the PT test, the source of TF utilized is thromboplastin and TF concentration is supraphysiological. This means that only the initiation phase of thrombin generation is required and the propagation and amplification phases are bypassed. The prothrombin time is therefore insensitive to many changes in the coagulation pathway and is incapable of detecting hypercoagulability [Fischer et al., U.S. Pat. No. 7,074,582].

[0008] Assays associated with the assessment of a hypercoagulable state include the Thrombin Anti-Thrombin Complex (TAT), Prothrombin fragment 1.2 (F1.2), and D-dimer. These blood tests are designed to measure a specific marker or product of the coagulation process. The TAT and F1.2 assays both measure late stages in the coagulation process while the D-dimer assay reflects both late stage of clot formation and fibrinolysis. These assays can exclude a thromboembolic disease but cannot foresee vascular complications or a risk of thrombotic event [Tejidor et al., U.S. Pat. No. 6,645,768].

[0009] U.S. Pat. No. 5,552,290 describes a method for detecting procoagulant platelet-derived microparticles (PDMP) in whole blood by flow cytometry. Total platelets are first identified using specific anti-platelet labeled agent (antibody against platelet-specific antigen, such as GPIb or GPIIb-IIIa). Then procoagulant PDMP are identified with a second agent specific for procoagulant PDMP (antibodies directed against coagulant factors, such as coagulant factor II, V, VIII, or X, or a protein, such as Annexin V). This method enables assessment of only PDMPs and not of procoagulant microparticles from other cellular origins. Also, this method does not allow evaluation of tissue factor or TFPI expression on microparticles.

[0010] U.S. Pat. No. 7,005,271 discloses a method for determining a thrombotic or prethrombotic state of an individual. The method utilizes immunoassays for detection and characterization of circulating blood microparticles and stimulated procoagulant cells. Essentially, blood derived microparticles are immobilized on a solid phase and prothrombinase activity in the immobilized complex is determined. Elevated level of prothrombinase activity determined for the immobilized complex compared with a level determined for normal body fluid samples (e.g., blood) indicates a thrombotic or prethrombotic state. There is no indication for determining TFPI in the microparticles or for determining the ratio of TF to TFPI on the microparticles.

[0011] U.S. Pat. No. 20020076833 discloses the identification of blood coagulation and related medical conditions by analyzing an expression level of various markers in whole blood, platelets and microparticles. Although measurement of TF and TFPI is indicated, their specific expression on microparticles is not contemplated nor is determination of their ratio on such particles.

[0012] Thus, currently, there is no coagulation assay that can measure TF or TFPI expression of particulated plasma and evaluate the expression ratio between particulated plasmatic TF and TFPI.

[0013] There is thus a widely recognized need for, and it would be highly advantageous to have a method of determining blood coagulation which is devoid of the above limitations.

SUMMARY OF THE INVENTION

[0014] According to one aspect of the present invention there is provided a method of determining a coagulation status of a blood sample, the method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the ratio is indicative of the coagulation status of the blood sample.

[0015] According to another aspect of the present invention there is provided a kit for determining a coagulation status of a blood sample, the kit comprising a packaging material which comprises at least one reagent for determining on microparticles of the blood sample an expression and/or activity ratio of TF and TFPI.

[0016] According to yet another aspect of the present invention there is provided a method of designing a treatment regimen for a subject in need thereof, the method comprising: (a) determining on cellular microparticles of a blood sample of the subject an expression and/or activity ratio of TF to TFPI, wherein the expression and/or activity ratio is indicative of the coagulation status of the subject; and (b) designing the treatment regimen based on the coagulation status;

[0017] According to further features in preferred embodiments of the invention described below, the at least one reagent for determining TF and TFPI expression ratio comprises an antibody.

[0018] According to still further features in the described preferred embodiments the antibody comprises a label.

[0019] According to still further features in the described preferred embodiments the antibody is attached to a solid support.

[0020] According to still further features in the described preferred embodiments the at least one reagent comprises a reagent for isolating cellular microparticles.

[0021] According to still further features in the described preferred embodiments the kit further comprising instructions for analyzing coagulation, the instructions comprises guidelines as follows:

[0022] (i) the coagulation status of the blood sample is considered normal when the expression ratio of TF to TFPI is below about 1;

[0023] (ii) the coagulation status of the blood sample demonstrates hyper-coagulability when the expression ratio of TF to TFPI is above 1;

[0024] (iii) the coagulation status of the blood sample may predict vascular complications and risk for thrombotic events when the expression ratio of TF to TFPI is above 3.

[0025] According to still further features in the described preferred embodiments the treatment is selected from the group consisting of Low molecular weight heparins (LMWH), warfarin, aspirin, heparin, NTHEs, Dipyridamole, Clopidogrel and Plateles glycoprotein IIb/IIIa antagonists.

[0026] According to still further features in the described preferred embodiments the cellular microparticles are selected from the group consisting of platelet derived microparticles, endothelial cell derived microparticles, leukocyte derived microparticles and erythrocyte derived microparticles.

[0027] According to still further features in the described preferred embodiments the determining the expression ratio of TF to TFPI is effected by a homogeneous assay.

[0028] According to still further features in the described preferred embodiments the determining the expression ratio of TF to TFPI is effected by a heterogeneous assay.

[0029] According to still further features in the described preferred embodiments the method further comprising isolating the cellular microparticles from the blood sample prior to the determining the ratio of TF to TFPI.

[0030] According to still further features in the described preferred embodiments the blood sample comprises a diluted blood sample.

[0031] According to still further features in the described preferred embodiments the blood sample comprises an undiluted blood sample.

[0032] According to still further features in the described preferred embodiments the blood sample is selected from a group consisting of a whole blood, a fractionated whole blood, a blood plasma and microparticles.

[0033] According to still further features in the described preferred embodiments the determining the expression ratio of TF to TFPI is effected by FACS.

[0034] According to still further features in the described preferred embodiments the activity ratio is determined by a clotting assay.

[0035] According to still further features in the described preferred embodiments when the expression ratio of TF to TFPI is below about 1, the coagulation status of the blood sample is normal.

[0036] According to still further features in the described preferred embodiments when the expression ratio of TF to TFPI is above about 1 the coagulation status of the blood sample demonstrates hyper-coagulability.

[0037] According to still further features in the described preferred embodiments when the expression ratio of TF to TFPI is above about 3, the coagulation status of the blood sample is predictive of the risk for thrombotic events.

[0038] The present invention successfully addresses the shortcomings of the presently known configurations by providing a novel method and kit of determining blood coagulation.

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

[0040] The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

[0041] In the drawings:

[0042] FIGS. **1**A-D are graphs showing TF and TFPI expression on microparticles (MPs) obtained from a healthy non-pregnant female as determined by FACS. FIG. **1**A is a graph of the calibration beads—0.75 micron presented in dot plot. FIG. **1**B is a graph showing anti-mouse FITC IgG-labeled sample which is used as a negative control. The M**1** gate is indicated for the area of the labeled population (R**1**). FIG. **1**C is a graph showing TF labeled microparticles. M**1** depicts TF-positive labeled microparticles. FIG. **1**D is a graph showing TFPI labeled microparticles. M**1** depicts TFPI-positive labeled microparticles.

[0043] FIG. **2** is a graph showing TF and TFPI expression and expression ratio on MPs in subjects with varied coagulation states as determined by FACS. The graph depicts TF or TFPI expression as percent of the total number of MPs in the gate. The TF/TFPI ratio reflects the coagulation status of the patient. Of note, open bars indicate TF expression, diagonal lines indicate TFPI expression and closed bars indicate TP/TFPI expression ratio. Shown are: TF and TFPI expression and expression ratio on MPs obtained from healthy non-pregnant women used as the control group (n=40); TF and TFPI expression and expression ratio on MPs obtained from healthy pregnant women indicated as normal pregnant (n=44); TF and TFPI expression and expression ratio on MPs obtained from pregnant women with gestational vascular complications (GVC, n=24); and TF and TFPI expression and expression ratio on MPs obtained from pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=20).

[0044] FIG. **3** is a graph showing TF/TFPI expression ratio on MPs in diabetic subjects as determined by FACS. MPs of healthy control volunteers (over 42 years of age, n=17, indicated by open bar), diabetic patients without known complications (n=13, indicated by diagonal lines bar), diabetic patients with cardio vascular complications (n=21, indicated by dotted bar) and diabetic patients with diabetic foot (n=22, indicated by closed bar).

[0045] FIG. **4** is a graph showing TF activity on MPs in women subjects with varied coagulation states as measured by a one-step clotting assay. The clotting times were converted to standard curve of 10-1000 arbitrary units of TF (AU/ml)—where 180 seconds of clotting time stand for 1 TF AU, 130 seconds of clotting time stand for 1.5 TF AU and 100 seconds of clotting time stand for 2.5 TFAU. Shown are: TF activity on MPs obtained from healthy non-pregnant women used as the control group (n=7); TF activity on MPs obtained from healthy pregnant women indicated as pregnant (n=7); TF activity on MPs obtained from pregnant women with gestational vascular complications (GVC) treated with anticoagulant low molecular weight heparin (LMWH, n=7); and TF activity on MPs obtained from pregnant women with GVC (n=7).

[0046] FIG. **5** is a graph showing TFPI antigen levels on MPs in women subjects with varied coagulation states. TFPI protein levels were measured in human MPs extracts by ELISA and expressed as TFPI ng/100 μg of MPs total proteins. Shown are: TFPI antigen level on MPs obtained from healthy non-pregnant women used as the control group (n=6); TFPI antigen level on MPs obtained from healthy pregnant women indicated as pregnant (n=7); TFPI antigen level on MPs obtained from pregnant women with gestational vascular complications (GVC, n=8); and TFPI antigen level on MPs obtained from pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=8).

[0047] FIG. **6** is a graph showing TF activity (shown in FIG. **4**) to TFPI antigen level (shown in FIG. **5**) ratio on MPs in women subjects with varied coagulation states. The TF activity/TFPI antigen ratio reflects the coagulation status of the patient. Shown are: TF activity/TFPI antigen ratio on MPs obtained from healthy non-pregnant women used as the control group (n=7); TF activity/TFPI antigen ratio on MPs obtained from healthy pregnant women indicated as pregnant (n=7); TF activity/TFPI antigen ratio on MPs obtained from pregnant women with gestational vascular complications (GVC, n=7); and TF activity/TFPI antigen ratio on MPs obtained from pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=7).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] The present invention is of a coagulation method and kit which can be used for diagnosing the coagulation status of blood samples.

[0049] The principles and operation of the method according to the present invention may be better understood with reference to the drawings and accompanying descriptions.

[0050] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

[0051] Procoagulant microparticles are associated with changes in the coagulation balance and their quantity is

highly elevated in a wide range of diseases including diabetes, cancer and acute coronary syndromes. Tissue Factor (TF), the initiator of coagulation, and Tissue Factor Pathway Inhibitor (TFPI), which inhibits the coagulation cascade, are both exposed as membrane antigens on the outer membrane of microparticles and influence the coagulation homeostasis.

[0052] At present, methods of assessing coagulation do not evaluate TF to TFPI expression ratio in microparticles. Coagulation assays and diagnostic kits available commercially are based on clotting time and do not entirely mimic the physiological coagulation reaction nor are able to detect hypercoagulability [Fischer et al., U.S. Pat. No. 7,074,582].

[0053] U.S. Pat. No. 5,552,290 teaches a method of detecting procoagulant platelet-derived microparticles (PDMP) in whole blood by flow cytometry. This method is not appropriate for assessment of microparticles that are of other cellular origins and does not allow evaluation of TF or TFPI expression on microparticles.

[0054] U.S. Pat. No. 20020076833 teaches the identification of blood coagulation by analysis of expression levels of various markers in whole blood, platelets and microparticles. Although this method allows evaluation of TF and TFPI, it does not hint to their specific expression on microparticles nor their expression ratio.

[0055] U.S. Pat. No. 7,005,271 teaches characterization of prothrombinase activity in microparticles similarly to the aforementioned application. This method does not mention TFPI expression in microparticles nor determines TP to TFPI expression ratio in microparticles.

[0056] Whilst reducing the present invention to practice, the present inventors have discovered that TF to TFPI expression and/or activity ratio in cellular microparticles can be predictive of the blood coagulation status.

[0057] As is illustrated herein below and the Examples section which follows, the present inventors have revealed specific TF to TFPI ratios that can be predictive of blood coagulation status. For example, TF to TFPI expression ratio lower than 1 represents normal healthy human plasma (Example 1); TF to TFPI expression ratio above 1 demonstrates hypercoagulation; and TF to TFPI expression ratio higher than 3 may predict risk of vascular complications or thrombotic events (Examples 2 and 3).

[0058] These ratios were found predictive of hypercoagulation resultant of various conditions and disorders including pregnancy (Example 2), pregnancy associated with gestational vascular complications (GVC) (Example 2, FIG. **2**) and diabetes associated complications including cardio vascular conditions and diabetic foot (Example 3, FIG. **3**). These results conclusively show that the present teachings can be used for determining blood coagulation status in an accurate and simple manner.

[0059] Thus, according to one aspect of the present invention, there is provided a method of determining a coagulation status of a blood sample. The method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the expression ratio is indicative of the coagulation status of the blood sample.

[0060] As used herein, the phrase "coagulation status" refers to the coagulability of the blood which either provides hemostasis (also termed normal coagulation which refers to clot formation only at the site of vessel wall injury); displays an increased tendency for blood clotting and thromboembolism (hypercoagulation); or displays a bleeding tendency (hypocoagulation). Under physiological conditions, pro- and anti-coagulant mechanisms are delicately balanced to provide blood hemostasis. Disturbances in this balance result in either bleeding or thromboembolic disorders, and can be induced by medical conditions, congenital or acquired, or by the intake of drugs or vitamins.

[0061] As used herein, the phrase "blood sample" refers to a blood sample that contains cellular microparticles. According to a preferred embodiment of this aspect of the present invention, the blood sample may be fresh whole blood, fractionated whole blood, blood plasma and/or microparticles.

[0062] As used herein, the phrase "cellular microparticles" refers to all blood cell derived microparticles. These microparticles are usually formed as a result of shedding (such as following cell activation, complement activity) and/or cell lysis (such as resulting from apoptosis). Examples of cellular microparticles which can be used in accordance with the present invention include, but are not limited to, platelet derived microparticles, endothelial cell derived microparticles, leukocyte derived microparticles and erythrocyte derived microparticles.

[0063] Blood withdrawal is effected using any procedure which is known in the art and provides enough material (cellular microparticles) for analysis. For example, normal venous blood collection procedures are used. Care is taken to not force blood from the subjects' veins. It is possible to use whole blood or plasma. It is especially preferred to use platelet poor plasma (PPP, see general materials and methods of the Examples section which follows). Preferably the sample is supplemented with an anticoagulant solution containing, for example, sodium citrate. The composition of the anticoagulant solution for collection of blood samples should keep platelet activation at a level as low as possible.

[0064] If needed microparticle enrichment may be effected by immobilizing this fraction to a solid support such as by immunoisolation using a microparticle specific antibody or antibodies. Accordingly, a concentration and separation of these microparticles from other blood cells and other blood or vascular compounds is possible. U.S. Pat. No. 7,005,271 provides detailed description for such an enrichment step. Any solid support may be used in such a configuration, preferably used are those which are compatible with automatic machinery such as multiwell plates, which can be used for high throughput analysis. Examples of such solid supports include, but are not limited to tubes, beads, microtiterplates or microcarriers made of plastics for example polystyrol, polyvinyl, polypropylene, polycarbonate, polysaccharide, silicone or glass [Maggio, Enzyme Immunoassays, CAP. Press, Florida (1980), 175-180; EP-A-0 063064, Bioengineering 16 (1974), 997-1003; Sonderson and Wilson, Immunology (1971) 20:1061-1065]. The microcarriers could be used as small columns.

[0065] As mentioned hereinabove, the expression and/or activity ratio of TF to TFPI in cellular microparticles of the blood sample is determined.

[0066] As used herein, the phrase "tissue factor (TF)" also termed thromboplastin, factor III or CD142 refers to the protein present as membrane receptor in subendothelial tissue, platelets, leukocytes and microparticles derived therefrom. TF is required for thrombin formation from the zymogen prothrombin, a stage which initiates the blood coagulation cascade.

[0067] As used herein, the phrase "tissue factor pathway inhibitor" refers to the single-chain polypeptide protein

receptor which is present in platelets and endothelial cells. Tissue Factor Pathway Inhibitor (TFPI) regulates TF activity by inhibiting the FVIIa-TF complex and thus inhibits the coagulation cascade.

[0068] As used herein, the phrase "expression ratio" refers to the protein expression ratio of TF to TFPI in the above-described microparticles.

[0069] Determining TF to TFPI expression ratio in the microparticles can be effected using a homogeneous or heterogeneous assay. Homogeneous assays may be effected as described in U.S. Pat. No. 5,552,290. Heterogeneous assays refer to two phase assays, usually involving the immobilization of the microparticles on a solid support.

[0070] Determining TF to TFPI expression ratio at the protein level can be effected using methods which are well known in the art. Examples include, but are not limited to immunoassays, such as ELISA, FACS, Western blot and the like. As shown in Examples 1 and 5 of the Examples section which follows, TF to TFPI expression ratio was determined by FACS and TFPI antigen level was determined by ELISA.

[0071] As used herein, the phrase "activity ratio" refers to the ratio of TF activity to TFPI activity in the above-described microparticles.

[0072] As used herein "TF activity" refers to pro-coagulation activity which is TF dependent. TF activity can be determined by assaying the clotting time of the microparticles using methods which are know in the art. For example, adding calcium and clotting factors (such as VIIa) to the microparticles and measuring clotting time (e.g., seconds) that may be converted to TF arbitrary units or the subsequent rate of factor Xa generation by chromogenic substrate.

[0073] As used herein "TFPI activity" refers to an anticoagulation activity which is TFPI dependent. TFPI is typically examined by a chromogenic activity assay. Basically, MPs are incubated with reagent mixture containing 0.8 nM activated factor X (Chromogenix-IL, Milan, Italy), 25 pM FVII (Sigma), 10 mM $CaCl_2$, 1% TF (Innovin) in tris saline citrate buffer (0.05 M tris, 0.1 M NaCl, 0.01 M Na_3 Citrate, 0.2% BSA (Sigma, pH8.0) for 20 minutes at 37° C., followed by the addition of 0.4 U/ml FX (20 μl) and further incubation for 10 minutes. A chromogenic substrate for FXa—0.72 mM S2765 (Chromogenix) is then added and incubated for 1 hour. The reaction is then terminated with 50% acetic acid (50 μl). Absorbance is read at 405 nm and may be compared to a standard curve. TFPI activity may be expressed as percent inhibition of control.

[0074] The present inventors have uncovered that a hybrid ratio of TF activity (also referred to herein as functional TF) to TFPI expression (also referred to herein as TFPI antigen level) on microparticles can also be indicative of the coagulation status of the blood sample.

[0075] The present inventors have shown that TF to TFPI expression ratio of microparticles may be predictive of coagulation status. Thus, a TF to TFPI expression ratio lower than about 1 is indicative of normal coagulation; a TF to TFPI expression ratio higher than about 1 indicates hypercoagulation, while TF to TFPI expression ratio higher than about 3 may be indicative of a risk of vascular complications or thrombotic events. Similar results were obtained with the determination of functional TF to TFPI antigen level (i.e., expression) ratio as shown in Example 6.

[0076] Reagents (at least one) for determining expression and/or activity ratio of TF and TFPI in microparticles of blood samples may be included in a packaging kit.

[0077] Examples of such reagents may include antibodies directed at TF and TFPI (such markers are commercially available, see Examples section which follows).

[0078] According to a preferred embodiment of this aspect, the antibody comprises a label. The label can be an enzyme, chemiluminescent, fluorescent or any other label which will allow detection of the antibody. Alternatively, indirect labeling (e.g., secondary antibodies) may be used.

[0079] Examples of reagents which may be used for determining TFPI and TF activity include but are not limited to chromogenic substrate and coagulation factors such as described hereinabove.

[0080] As mentioned hereinabove, TF to TFPI expression ratio in microparticles may be predictive of a risk of hypercoagulation or prothrombosis. Thus, the present methodology may be valuable in determining treatment regimen for subjects in need thereof.

[0081] Thus, according to another aspect of the present invention, there is provided a method of designing a treatment regimen for a subject in need thereof. The method comprising, determining on microparticles of a blood sample of the subject an expression and/or activity ratio of TF to TFPI as described above. The expression and/or activity ratio is indicative of the coagulation status of the subject; and designing the treatment regimen based on the coagulation status;

[0082] As used herein, the term "subject" refers to a mammalian subject, preferably a human subject. The subject may be at risk of hypercoagulation (e.g., predisposed) either because of a physiological state (e.g., pregnancy, a medical condition which affects, or results from abnormal blood coagulation), drug use or environmental or genetic predisposition.

[0083] Examples of medical conditions which affect or result from abnormal blood coagulation include, but are not limited to, disorders of the platelet and vessel wall [Immune thrombocytopenic purpura (ITP), Thrombotic thrombocytopenic purpura (TTP), Hemolytic-uremic syndrome (HUS), Glanzmann's thrombasthenia, Bernard-Soulier syndrome, Storage pool disorders, Paroxysmal nocturnal hemoglobinuria, Gray platelet syndrome: deficient alpha granules, Delta storage pool deficiency: deficient dense granules], disorders of coagulation and thrombosis [Disseminated intravascular coagulation, Factor deficiencies: Hemophilia A (Factor VIII deficiency), Hemophilia B (Factor IX deficiency, "Christmas disease"), Hemophilia C (Factor XI deficiency), Von Willebrand disease, Factor inhibitors, Platelet Dysfunction], disorders predisposing to thrombosis [Heparin-induced thrombocytopenia and thrombosis ("white clot syndrome"), Antiphospholipid syndrome, Lupus anticoagulant, Anticardiolipin antibody, Factor V Leiden, Activated Protein C Resistance, Prothrombin mutation, Protein C deficiency, Protein S deficiency, Antithrombin deficiency, Abnormally raised levels of Factor VIII and Factor XI], acute coronary syndromes, peripheral arterial diseases, diabetes mellitus, disseminated intravascular coagulation (DIC), cancer, systemic inflammatory diseases, atherosclerosis, thromboembolism, pulmonary embolism and pregnancy

[0084] As used herein, the phrase "treatment regimen" refers to a treatment plan that specifies the type of treatment, dosage, schedule and/or duration of a treatment provided to a subject in need thereof (e.g., a subject diagnosed with a pathology). The selected treatment regimen can be an aggressive one which is expected to result in the best clinical outcome (e.g., complete cure of the pathology) or a more mod-

erate one which may relieve symptoms of the pathology yet results in incomplete cure of the pathology. It will be appreciated that in certain cases the more aggressive treatment regimen may be associated with some discomfort to the subject or adverse side effects (e.g., damage to healthy cells or tissue). The type of treatment can include a surgical intervention (e.g., removal of lesion, diseased cells, tissue, or organ), a cell replacement therapy, an administration of a therapeutic drug (e.g., receptor agonists, antagonists, hormones, chemotherapy agents) in a local or a systemic mode, an exposure to radiation therapy using an external source (e.g., external beam) and/or an internal source (e.g., brachytherapy) and/or any combination thereof. The dosage, schedule and duration of treatment can vary, depending on the severity of pathology and the selected type of treatment, and those of skills in the art are capable of adjusting the type of treatment with the dosage, schedule and duration of treatment.

[0085] Thus, once coagulation status is determined in accordance with the teachings of the present invention (either one time determination or repetitively, as necessary), the subject may be treated with, for example, blood thinners such as Low molecular weight heparins (LMWH), warfarin, aspirin, heparin, NSAIDs, Dipyridamole, Clopidogrel and Plateles glycoprotein IIb/IIIa antagonists.

[0086] Thus, the present invention provides novel methods and kits for determining blood coagulation that can be employed for designing treatment regimen for numerous subjects in need thereof.

[0087] As used herein the term "about" refers to ±10%.

[0088] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

[0089] Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

[0090] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Md. (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York, Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, Calif. (1990); Marshak et al., "Strategies for Protein Purification and Characterization—A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

General Materials and Methods

[0091] Blood Collection and Preparation: The study was approved by the ethics comity of the Rambam Health Care Campus. 3 ml blood samples were collected into blood collection tubes containing 300 μl Sodium Citrate (1:10). Tubes were centrifuged twice at 1,500×g for 15 minutes in order to reach Poor-Platelet Plasma (PPP) state. The samples were then used in the assay kit or were stored for up to one week in a −80° C. freezer.

[0092] Antibodies: The following antibodies were used: mouse anti-human TF (American Diagnostica, Greenwich, Conn., USA); FITC conjugated mouse anti-human TF (American Diagnostica, Greenwich, Conn., USA); mouse anti-human TFPI (American Diagnostica, Greenwich, Conn., USA); rabbit anti mouse IgG FITC (DakoCytomation, Denmark); FITC conjugated mouse IgG (BD biosciences, Fremingham, Mass., USA) and Beads 0.75 micron (BD biosciences, Fremingham, Mass., USA).

[0093] Sample Labeling and FACS Analysis: Tubes containing 50 μl sample PPP were incubated for 30 minutes at room temperature (RT) with either FITC conjugated mouse anti-human TF antibody or FITC conjugated mouse anti-human TFPI antibody as primary antibodies. FITC conjugated mouse IgG was used as a secondary antibody and samples which were stained only with FITC conjugated mouse IgG were used as a negative control.

[0094] Samples stained with non conjugated antibodies, TF or TFPI, for 30 minutes at RT were then incubated with secondary antibody FITC anti mouse for 30 minutes, in the dark.

[0095] 450 μl FACS buffer (Phosphate buffer saline (PBS), Formaldehyde 1%, Azid 0.02%) was added to each tube.

[0096] All particles were identified by FACS analysis and are shown in FIG. **1**A. TF labeled microparticles and TFPI labeled microparticles were identified at the **M1** area (in FIGS. **1**B, D) and expressed as percent from the total microparticles in the gate.

[0097] Calculation of TF/TFPI Ratio: The ratio between TF and TFPI expression on microparticles was calculated as a measure of coagulation status. TF/TFPI ratio less than 1 rep-

resented normal healthy human plasma. TF/TFPI ratio higher than 1 demonstrated hyper-coagulability state. TF/TFPI ratio higher than 3 may predict a risk of vascular complication or a thrombotic event.

[0098] TF Activity: Plasmatic MPs were isolated using ultracentrifuge. MPs μg/μl TF activity was measured by a one-step clotting assay as was previously described (Aharon et al, Thromb Haemost (2004) 92(4):776-86). MPs extract. (100 μl) were added to pooled normal human plasma (100 μl) and incubated for one minute at 37° C. Then, a 25 mM calcium chloride solution (100 μl) was added. The clotting times were measured and converted to standard curve of 10-1000 arbitrary units of TF (AU/ml)—where 180 seconds of clotting time stand for 1 TF AU, 130 seconds stand for 1.5 TF AU and 100 sec stand for 2.5 TF AU.

[0099] Measurement of TFPI Antigen Levels by ELISA: Plasmatic MPs were isolated using ultracentrifuge. TFPI protein levels were measured in human MPs extracts by ELISA (American Diagnostica, Greenwich, Conn., USA) according to manufacturer's instructions and expressed as TFPI ng/100 μg of MPs total proteins.

[0100] Calculation of TF Activity/TFPI Antigen Level Ratio: The ratio between TF activity and TFPI antigen level on microparticles was calculated as a measure of coagulation status. TF activity/TFPI antigen ratio less than 1 represented normal healthy human plasma. TF activity/TFPI antigen ratio higher than 1 demonstrated hyper-coagulability state. TF activity/TFPI antigen ratio higher than 3 may predict a risk of vascular complication or a thrombotic event.

Example 1

Assessing the Ratio Between TF and TFPI Expression on Microparticles as the Method of the Present Invention

[0101] Results

[0102] To characterize the normal TF/TFPI ratio of blood microparticles (MPs), a blood sample of a healthy non-pregnant woman was analyzed for MPs TF and TFPI expression. FACS analysis was used to identify positively stained MPs. FACS mediated detection of MPs was calibrated with 0.75 micron beads as indicated in FIG. **1**A. Sample labeling with anti mouse FITC IgG served as the negative control (FIG. **1**B). The ratio between TF expression (6.4%, FIG. **1**C) and TFPI expression (18.5%, FIG. **1**D) on microparticles was calculated (0.35). The TF/TFPI ratio was lower than 1 which represented normal healthy human plasma.

Example 2

Determining TF and TFPI Expression Ratio on MPs of Women as a Method to Assess Hyper-Coagulation and Pro-Thrombotic Events in Pregnancy According to the Teachings of the Present Invention

[0103] Results

[0104] Four Groups of Women: non-pregnant healthy women (control group, n=40), healthy pregnant women (normal pregnant, n=44), pregnant women with gestational vascular complications (GVC, n=24) and pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=20) were examined to characterize the thrombogenic potential of microparticles. The expression of TF or TFPI and their ratio on blood microparticles was assessed.

[0105] As shown in FIG. **2**, expression of TF on microparticles was significantly higher in pregnant women compared to non-pregnant women aged 22-40 years old (p=0.0002). There was no marked difference between TF expression in the three different pregnant women groups (healthy, with GVC or with GVC treated with LMWH).

[0106] The results also demonstrate that expression of TFPI on microparticles was relatively high in non-pregnant women whereas it was significantly lower in normal pregnant women (p<0.0001). Expression of TFPI was even lower in pregnant women with GVC (p=0.41) a value which rose significantly in pregnant women with GVC treated with enoxaparin (LMWH, p=0.042).

[0107] The microparticle TF/TFPI ratio in non-pregnant women was 0.396 (±0.195). The ratio increased significantly to 2.78 (±0.124, p=0.0092) in normal pregnant women and increased even more significantly to 4.17 (±2.32, p=0.0092) in pregnant women with GVC. The microparticle TF/TFPI ratio was significantly reduced in the LMWH treated group 1.58 (±0.437, p=0.0001) compared to non-treated GVC pregnant women.

[0108] The results demonstrated that microparticle TF/TFPI ratio was lower than 1 in non-pregnant healthy woman as expected in normal healthy human plasma. In healthy pregnant women, the microparticle TF/TFPI ratio was higher than 1 which implies a hyper-coagulability state. In pregnant women with known gestational vascular complications, the microparticle TF/TFPI ratio was higher than 3 which may predict a thrombotic event. The TF/TFPI ratio was significantly reduced in the LMWH treated group.

Example 3

Determining TF and TFPI Expression Ratio on MPs of Subjects With Diabetes as a Method to Assess Hyper-Coagulation and Pro-Thrombotic Events According to the Teachings of the Present Invention

[0109] Results

[0110] To characterize the thrombogenic potential of microparticles, blood was obtained from healthy volunteers (control group, n=17), diabetic healthy patients (n=13), diabetic patients with cardiovascular complications (n=21) and patients with diabetic foot (n=22). The expression of TF and TFPI on microparticles and their ratio was assessed.

[0111] As shown in FIG. **3**, the TF/TFPI ratio on microparticles of the healthy control group was 0.43 (±0.268) and was significantly increased in diabetic patients without known complications 1.41 (±0.734, p>0.0001). The TF/TFPI ratio was further increased in diabetic patients with cardio vascular complications 2.8 (±2.08, p=0.028) or with diabetic foot 2.38 (±2.7, p=0.021).

[0112] The results demonstrated that microparticle TF/TFPI ratio was lower than 1 in the healthy control group as expected in normal healthy human plasma. The microparticle TF/TFPI ratio increased to higher than 1 in all diabetic patients, with even higher ratio values in diabetic patients with diabetic foot, which implies a hyper-coagulability state. In diabetic patients with cardio vascular complications the microparticle TF/TFPI ratio may predict a thrombotic event.

Example 4

Determining MP TF Activity in Women Population Groups

[0113] Results

[0114] Four Groups of Women: non-pregnant healthy women (control group, n=7), healthy pregnant women (pregnant, n=7), pregnant women with gestational vascular complications (GVC, n=7) and pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=7) were examined to characterize the procoagulant potential of microparticles. TF activity on blood microparticles was assessed.

[0115] As demonstrated in FIG. **4**, TF activity on microparticles was significantly lower in non-pregnant women compared to pregnant women ($p<0.0001$). There was no marked difference between TF activity in the three different pregnant women groups (healthy, with GVC treated with LMWH or untreated with GVC).

Example 5

Determining MP TFPI Antigen Levels in Women Population Groups

[0116] Results

[0117] Four Groups of Women: non-pregnant healthy women (control group, n=6), healthy pregnant women (pregnant, n=7), pregnant women with gestational vascular complications (GVC, n=8) and pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=8) were examined to characterize the anticoagulant potential of microparticles. TFPI antigen levels on blood microparticles were assessed.

[0118] As demonstrated in FIG. **5**, TFPI antigen level on microparticles of non-pregnant healthy women was significantly higher compared to pregnant healthy women 1.322 ± 0.0258; 0.504 ± 0.0161 respectively ($p<0.0001$). TFPI antigen level was even lower in pregnant women with GVC 0.236 ± 0.013 ($p<0.0001$), a value which rose in pregnant women with GVC treated with LMWH 0.445 ± 0.019 ($p<0.0001$).

Example 6

Determining TF Activity and TFPI Antigen Level Ratio in MPs of Women as a Method to Assess Hyper-Coagulation and Risk of Pro-Thrombotic Events in Pregnancy According to the Teachings of the Present Invention

[0119] Results

[0120] To characterize the thrombogenic potential of microparticles, blood was obtained from healthy non-pregnant women (control group, n=7), healthy pregnant women (pregnant, n=7), pregnant women with gestational vascular complications (GVC, n=7) and pregnant women with GVC treated with anticoagulant low molecular weight heparin (LMWH, n=7). TF activity to TFPI antigen level on blood microparticles was assessed.

[0121] As shown in FIG. **6**, TF activity/TFPI antigen ratio on microparticles of non-pregnant women was 0.657 ± 0.035. The ratio increased significantly to 2.82 ± 0.135 ($p<0.0001$) in healthy pregnant women and increased drastically to 6.135 ± 0.768 ($p<0.0001$) in pregnant women with GVC. The microparticle TF activity/TFPI antigen ratio was significantly reduced in the LMWH treated group to 3.198 ± 0.568 ($p<0.0001$) compared to non-treated GVC pregnant women.

[0122] The results demonstrated that microparticle TF activity/TFPI antigen ratio was lower than 1 in non-pregnant healthy woman as expected in normal healthy human plasma. In healthy pregnant women, the microparticle TF activity/TFPI antigen ratio was higher than 1 which implies a hyper-coagulability state. In pregnant women with known gestational vascular complications, the microparticle TF activity/TFPI antigen ratio was higher than 3 which may predict a risk of thrombotic event. The TF activity/TFPI antigen ratio was significantly reduced in the LMWH treated group.

[0123] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[0124] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications and GenBank Accession numbers mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application or GenBank Accession number was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

1. A method of determining a coagulation status of a blood sample, the method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein said ratio is indicative of the coagulation status of the blood sample.

2. A kit for determining a coagulation status of a blood sample, the kit comprising a packaging material which comprises at least one reagent for determining on microparticles of the blood sample an expression and/or activity ratio of TF and TFPI.

3. The kit of claim **2**, wherein said at least one reagent for determining TF and TFPI expression ratio comprises an antibody.

4. The kit of claim **2**, wherein said antibody comprises a label.

5. The kit of claim **2**, wherein said antibody is attached to a solid support.

6. The kit of claim **2**, wherein said at least one reagent comprises a reagent for isolating cellular microparticles.

7. The kit of claim **2**, further comprising instructions for analyzing coagulation, said instructions comprise guidelines as follows:

(i) the coagulation status of the blood sample is considered normal when said expression ratio of TF to TFPI is below about 1;

(ii) the coagulation status of the blood sample demonstrates hyper-coagulability when said expression ratio of TF to TFPI is above 1;

(iii) the coagulation status of the blood sample may predict vascular complications and risk for thrombotic events when said expression ratio of TF to TFPI is above 3.

8. A method of designing a treatment regimen for a subject in need thereof, the method comprising:

(a) determining on cellular microparticles of a blood sample of the subject an expression and/or activity ratio of TF to TFPI, wherein said expression and/or activity ratio is indicative of the coagulation status of the subject; and

(b) designing the treatment regimen based on said coagulation status.

9. The method of claim **8**, wherein the treatment is selected from the group consisting of Low molecular weight heparins (LMWH), warfarin, aspirin, heparin, NSAIDs, Dipyridamole, Clopidogrel and Plateles glycoprotein IIb/IIIa antagonists.

10. The method of claim **1**, wherein said cellular microparticles are selected from the group consisting of platelet derived microparticles, endothelial cell derived microparticles, leukocyte derived microparticles and erythrocyte derived microparticles.

11. The method of claim **1**, wherein said determining said expression ratio of TF to TFPI is effected by a homogeneous assay.

12. The method of claim **1**, wherein said determining said expression ratio of TF to TFPI is effected by a heterogeneous assay.

13. The method of claim **1**, further comprising isolating said cellular microparticles from the blood sample prior to said determining said ratio of TF to TFPI.

14. The method of claim **1**, wherein the blood sample comprises a diluted blood sample.

15. The method of claim **1**, wherein the blood sample comprises an undiluted blood sample.

16. The method of claim **1**, wherein the blood sample is selected from a group consisting of a whole blood, a fractionated whole blood, a blood plasma and microparticles.

17. The method of claim **1**, wherein said determining said expression ratio of TF to TFPI is effected by FACS or ELISA.

18. The method of claim **1**, wherein said activity ratio is determined by a clotting assay.

19. The method of claim **1**, wherein when said expression ratio of TF to TFPI is below about 1, the coagulation status of the blood sample is normal.

20. The method of claim **1**, wherein when said expression ratio of TF to TFPI is above about 1 the coagulation status of the blood sample demonstrates hyper-coagulability.

21. The method of claim **1**, wherein when said expression ratio of TF to TFPI is above about 3, the coagulation status of the blood sample is predictive of the risk for thrombotic events.

* * * * *

patsnap

专利名称(译)	确定凝血的方法和试剂盒		
公开(公告)号	US20090042217A1	公开(公告)日	2009-02-12
申请号	US12/223290	申请日	2007-01-28
申请(专利权)人(译)	拉帕波特家庭研究学院医学科学		
当前申请(专利权)人(译)	拉帕波特家庭研究学院医学科学		
[标]发明人	BRENNER BENJAMIN AHARON ANAT		
发明人	BRENNER, BENJAMIN AHARON, ANAT		
IPC分类号	G01N33/543 C12Q1/56 G01N33/53		
CPC分类号	G01N33/4905 G01N2333/7454 G01N33/86		
优先权	60/762519 2006-01-27 US		
外部链接	Espacenet USPTO		

摘要(译)

提供了一种确定血液样本的凝固状态的方法。该方法包括测定血液样品的细胞微粒中组织因子（TF）与组织因子途径抑制剂（TFPI）的表达和/或活性比，其中该比率指示血液样品的凝固状态。